Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272654 | 0.85 | LOXL2 (0.35) | ALDH1A1LOXL2RXRAGRIN1GRIN2B | |
| SCHEMBL84449 | 0.80 | LOXL2 (0.42) | ALDH1A1LOXL2LMNACYP3A4AAK1 | |
| SCHEMBL12394763 | 0.79 | HRH4 (0.40) | ALDH1A1RXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL25135431 | 0.78 | CHRNA7 (0.39) | ALDH1A1RXRAGRIN1GRIN2B | |
| SCHEMBL24946111 | 0.78 | LOXL2 (0.30) | LOXL2 | |
| SCHEMBL21398388 | 0.78 | LOXL2 (0.39) | LOXL2KDM4ELMNACYP3A4TSHR | |
| SCHEMBL26791964 | 0.78 | LOXL2 (0.35) | ALDH1A1LOXL2RXRAGRIN1GRIN2B | |
| SCHEMBL20143958 | 0.77 | LMNA (0.40) | ALDH1A1RXRAGRIN1GRIN2BLMNA | |
| SCHEMBL19821720 | 0.75 | KDM4E (0.35) | ALDH1A1RXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL18507169 | 0.75 | LOXL2 (0.30) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | ALDH1A1 1726/4885LOXL2 32/4885RXRA 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.